Immuno-oncology imaging firm ImaginAb has started patient enrolment in a Phase II clinical trial of its CD8 tracer 89Zr-Df-IAB22M2C to visualise T-cells and enable personalised treatment.

The first patient has been enrolled at City of Hope, a research and treatment centre in Los Angeles County, California, US.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

89Zr-Df-IAB22M2C is an imaging agent that uses non-invasive, whole-body in-vivo PET imaging of CD8 T cells to visualise the immune system.

The technology leverages ImaginAb’s Minibody platform to target and visualise CD8+ T-cells to offer specific and quantitative assessment of the immunological status of each cancer lesion in a patient.

This approach is expected to facilitate tailored treatment based on the needs of individual patients.

ImaginAb CEO Ian Wilson said: “ImaginAb’s goal is to provide target-specific imaging agents to predict, inform, monitor and enable treatment of cancer disease more effectively.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

City of Hope expands the ImaginAb active sites performing Phase II baseline / on-treatment trials to evaluate the use of 89Zr-Df-IAB22M2C.

During the trial, the PET tracer’s utility in imaging CD8 T cells before (baseline) and after (on-treatment) cancer patients undergo immunotherapy-based treatment will be investigated.

Metastatic cancer patients will be recruited into the trial, which will explore the link between imaging signals observed using ImaginAb’s ImmunoPET imaging agent, standard-of-care scans and also immunohistochemistry analysis of CD8 in biopsied tissues.

The study will also measure changes in CD8+ T-cell distribution prior to and after immuno-oncology therapies.

ImaginAb is developing a pipeline of in-vivo antibody-based imaging agents to drive the development of therapeutic antibodies, diagnose disease, and aid precision medicine.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact